Suppr超能文献

大鼠静脉注射和口服芘后1-羟基芘的尿排泄和胆汁排泄动力学

Urinary and biliary excretion kinetics of 1-hydroxypyrene following intravenous and oral administration of pyrene in rats.

作者信息

Bouchard M, Viau C

机构信息

Département de médecine du travail et d'hygiène du milieu, Faculté de médecine, Université de Montréal, Québec, Canada.

出版信息

Toxicology. 1998 May 15;127(1-3):69-84. doi: 10.1016/s0300-483x(98)00033-x.

Abstract

The urinary and biliary excretion kinetics of 1-hydroxypyrene (1-OHP) were compared in male Sprague-Dawley rats exposed intravenously and orally to 1.5, 5, 15, 50 and 100 micromol/kg pyrene. Urine and bile samples were collected at 6-h intervals for up to 24 h. Results showed that the kinetics of 1-OHP were similar for both biliary and urinary excretion whatever the administered dose or exposure route. Furthermore, the time course of 1-OHP excretion in either bile or urine following intravenous dosing resembled that observed after oral administration. In addition, the exposure route and dose had no significant effect on the fraction of dose recovered in urine and bile as 1-OHP after 6, 12, 18 and 24 h post-dosing. Following intravenous injection of 1.5, 5, 15, 50 and 100 micromol/kg pyrene, the mean cumulative percent of dose excreted as 1-OHP in urine over 24 h ranged from 1.7 to 3.2%, while biliary values ranged from 6.5 to 9.5%. Correspondingly, after oral administration, on average, 2.6-3.3% of dose was excreted as 1-OHP in urine and 7.9-10.9% was recovered in bile. Overall, the linear dose-excretion relationship following either exposure routes supports the usefulness of 1-OHP in urine as a bioindicator of polycyclic aromatic hydrocarbon (PAH) exposure. Results further suggest that tissue uptake and distribution of intravenously and orally administered pyrene proceeds similarly. By comparing these data with predicted values from a previously published physiologically based pharmacokinetic model for pyrene in the rat, it also appears that a small fraction of pyrene dose (12%) remains in the body after 24 h and that metabolites other than 1-OHP as measured in the current study are present in significant proportions in urine and feces.

摘要

在静脉注射和口服给予1.5、5、15、50和100微摩尔/千克芘的雄性Sprague-Dawley大鼠中,比较了1-羟基芘(1-OHP)的尿排泄和胆汁排泄动力学。每隔6小时收集尿液和胆汁样本,持续24小时。结果表明,无论给药剂量或暴露途径如何,1-OHP的胆汁排泄和尿排泄动力学相似。此外,静脉给药后胆汁或尿液中1-OHP排泄的时间进程与口服给药后观察到的相似。此外,给药后6、12、18和24小时,暴露途径和剂量对尿液和胆汁中作为1-OHP回收的剂量分数没有显著影响。静脉注射1.5、5、15、50和100微摩尔/千克芘后,24小时内尿液中作为1-OHP排泄的剂量平均累积百分比范围为1.7%至3.2%,而胆汁中的值范围为6.5%至9.5%。相应地,口服给药后,平均有2.6%-3.3%的剂量以1-OHP的形式排泄到尿液中,7.9%-10.9%在胆汁中回收。总体而言,两种暴露途径后的线性剂量-排泄关系支持尿液中1-OHP作为多环芳烃(PAH)暴露生物标志物的有用性。结果进一步表明,静脉注射和口服芘的组织摄取和分布过程相似。通过将这些数据与先前发表的大鼠芘生理药代动力学模型的预测值进行比较,还发现24小时后芘剂量的一小部分(12%)保留在体内,并且在本研究中测量的1-OHP以外的代谢物在尿液和粪便中占相当大的比例。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验